Ingenuity Pathway Analysis identifies the molecular and cellular functions (left panel) and diseases and disorders (right panel) which most significantly associate with the 158 SRF-dependent and androgen-responsive gene signature (A). Unsupervised clustering using the 158 gene/178 probe sets signature separates normal from cancerous prostate samples. Gleason pattern nomenclature 0, 1, 6 and 7 correspond to normal epithelium, BPH, PIN and LN metastases samples, respectively. Tissue type designation C, L, B, N and P refers to localized cancer, LN metastases, BPH, normal epithelium and PIN, respectively. Cancer samples are marked as ‘Y’ and non-cancer samples are marked as ‘N’ (B). Differential expression analysis for the 178 probe sets between cancer (PIN, primary and metastatic prostate cancer) and non-cancer (BPH and normal prostate) samples was conducted using parametric t test. A volcano plot was created to visualize the results using – log 10 (p value) as y-axis and log2 fold change as x-axis. Probe sets which are differentially expressed (p<0.05) are listed in Table S4 (C).